A Phase 2a Study of LLX-424 in Patients With a History of Kidney Stones
Completed · Phase 2 · Has a placebo group
Conditions studied: Kidney Stones
In brief
This is a Phase 2a study of glycolate oxidase inhibitor LLX-424 in patients with a history of kidney stones. Eligible subjects with a history of kidney stones will be randomized to receive study drug (LLX-424 or placebo) for 8 weeks.
Key facts
- Study ID
- NCT06932146
- Run by
- Lilac Therapeutics, Inc.
- People needed
- 51
- Starts
- 2025-03-23
- Expected to finish
- 2025-09-30
- Last updated by the study team
- 2025-10-29
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- History of kidney stones documented in medical records
- 24-hour urine oxalate excretion
- Body mass index 18.5 to 38 kg/m2 inclusive
- Estimated glomerular filtration rate ≥ 60 mL/min/1.73m2
You may not qualify if…
- History or medical record evidence of kidney stones that are not calcium oxalate
- Unstable kidney function
- Spot urine protein to creatinine ratio ≥ 1 mg/mg at screening
- History of kidney transplantation
- Hemoglobin A1c > 9.5% at screening
- History of enteric hyperoxaluria, intestinal malabsorption, bariatric surgery, intestinal surgery, inflammatory bowel disease
- History or evidence of cirrhosis
Where it is running
- Clinical Research Site #2 — Saint Paul, Minnesota, United States
- Clinical Research Site #3 — Springfield, Missouri, United States
- Clinical Research Site #1 — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.